Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.

被引：0
|
作者：
Celio, Luigi
Bonizzoni, Erminio
Bria, Emilio
机构：
[1] Desenzano Garda Hosp, Oncol Unit, ASST Garda, Brescia, Italy
[2] Univ Milan, Fac Med & Surg, Sect Med Stat Biometry & Epidemiol GA Maccacaro, Dept Clin Sci & Commun, Milan, Italy
[3] Univ Cattolica Sacro Cuore, IRCCS, Fdn Policlin Univ Agostino Gemelli, Med Oncol,Comprehens Canc Ctr, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.12093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12093
引用
收藏
页数：3
相关论文
共 50 条
  • [11] NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.
    Jordan, Karin
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [12] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
    Gralla, R. J.
    Bosnjak, S. M.
    Hontsa, A.
    Balser, C.
    Rizzi, G.
    Rossi, G.
    Borroni, M. E.
    Jordan, K.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1333 - 1339
  • [13] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
    Aapro, M.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Lorusso, V.
    Karthaus, M.
    Grunberg, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
  • [14] Effectiveness of NEPA, an oral fixed-dose combination of NEtupitant and PAlonosetron in the prevention of chemotherapy-induced nausea-vomiting in patient receiving highly emetogenic chemotherapy regimens.
    Jadhav, Amit Y.
    Gupta, Sudeep
    Biswas, Ghanashyam
    Chandrakanth, M., V
    Dattatreya, Palanki Satya
    Thomas, Boben
    Gupta, Sumant
    Bhagat, Sagar B.
    Patil, Saiprasad
    Barkate, Hanmant B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
    Hesketh, Paul Joseph
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Alyasova, Anna
    Drobner, Igor
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [16] A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
    Aapro, M.
    Rugo, H.
    Rossi, G.
    Rizzi, G.
    Borroni, M. E.
    Bondarenko, I.
    Sarosiek, T.
    Oprean, C.
    Cardona-Huerta, S.
    Lorusso, V.
    Karthaus, M.
    Schwartzberg, L.
    Grunberg, S.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1328 - 1333
  • [17] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [18] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [19] Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients
    Agre, Suhas
    Agre, Madhura
    Pol, Pooja
    Tonse, Mubarakunnisa
    Mohanty, Mitasha
    Shaikh, Alfiya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [20] Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (> 65 years) fit for cisplatin: A sub-analysis from a phase 3 study
    Celio, Luigi
    Bartsch, Rupert
    Aapro, Matti
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (06)
12345